Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II cetuximab monotherapy in refractory metastatic colorectal cancer with KRAS mutation and favorable FcγRII/IIIa genotypes
2010-023580-18Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Feb 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cetuximab in colorectal cancer (CRC), sponsored by Merck & Co. Primary endpoint: Objective response rate (ORR) per RECIST v1.1. Started Feb 2011; status: completed.
02
Drugs
cetuximab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2010-023580-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023580-18.